Scott McClellan

Scott McClellan's Title

Scott McClellan currently holds the position of Team Lead in Clinical Development at Orca Bio. Joining the company in 2018, Scott has been instrumental in steering clinical research and development initiatives, primarily in the field of oncology and malignant hematology. His leadership role involves overseeing clinical trials and development programs, ensuring that they meet scientific and regulatory standards.

Scott McClellan's Company

Scott McClellan joined Orca Bio in 2018, a biotech company focusing on developing precision cell therapies. Orca Bio leverages advanced research in immune system modulation to create effective treatments for hematologic cancers and other severe conditions. Scott’s role as a Team Lead in Clinical Development is pivotal to the company’s mission of advancing clinical trials and regulatory approvals for innovative therapies.

Scott McClellan's Education and Expertise

Scott McClellan's extensive academic background includes earning a bachelor’s degree in biology from Birmingham-Southern College and both an MD and a PhD in immunology from Washington University in St. Louis School of Medicine. His education laid a robust foundation for his 13 years of research and development experience in oncology and malignant hematology. Scott’s expertise extends to leading clinical programs focused on T cell-directing bispecific antibodies and antibody-drug conjugates for lymphoma and multiple myeloma.

Scott McClellan's Background

Before joining Orca Bio, Scott McClellan served as a Medical Director at Genentech, where he focused on early clinical development in oncology. His tenure at Genentech included leading clinical programs that evaluated T cell-directing bispecific antibodies and antibody-drug conjugates for lymphoma and multiple myeloma. Scott has also held academic positions, such as being an Adjunct Clinical Assistant Professor of Medicine at Stanford University School of Medicine, where he treated patients in the hematology clinic at the Palo Alto VA Hospital and conducted research on acute lymphoblastic leukemia.

Scott McClellan's Achievements

Scott McClellan's career is marked by significant achievements in the field of oncology and hematology. At Genentech, he led groundbreaking clinical programs evaluating innovative treatments for lymphoma and multiple myeloma. His research and clinical work have contributed to the advancement of T cell-directing bispecific antibodies and antibody-drug conjugates. Additionally, his role as an Adjunct Clinical Assistant Professor at Stanford involved both treating patients and conducting critical research on acute lymphoblastic leukemia, further showcasing his dedication to advancing medical science and patient care.